03 July 2020 : Clinical Research
Risk Factors for Relapse of Childhood B Cell Acute Lymphoblastic Leukemia
Rongrong Zhang1BCDEF, Haiyan Zhu1BCDF, Yufang Yuan1CDEF*, Jiou Zhao2BCD, Xiaochun Yang1BCF, Zhaofang Tian1ACDEFGDOI: 10.12659/MSM.923271
Med Sci Monit 2020; 26:e923271
Table 1 Characteristics for the relapse and non-relapse groups of B-ALL patients.
| Subjects | Relapse group | Non-relapse group | χ2/t | p values |
|---|---|---|---|---|
| Gender | χ=0.033 | 0.855 | ||
| Male | 11 (47.83%) | 38 (50.00%) | ||
| Female | 12 (52.17%) | 38 (50.00%) | ||
| Age | χ=11.277 | 0.004 | ||
| Age <1 year | 4 (17.39%) | 8 (10.53%) | ||
| 1 year ≤ age <10 years | 14 (60.87%) | 66 (86.84%) | ||
| ≥10 years | 5 (21.74%) | 2 (2.63%) | ||
| Chemotherapy-induced agranulocytopenia time (days) | 9.13±8.22 | 17.00±10.81 | t=3.721 | 0.001 |
| WBC count in newly diagnosed peripheral blood | χ=5.800 | 0.016 | ||
| ≤100×10/L | 18 (78.26%) | 72 (94.74%) | ||
| >100×10/L | 5 (21.74%) | 4 (5.26%) | ||
| Newly diagnosed bone marrow progenitor cells (%) | 76.48±14.41 | 80.80±12.39 | t=1.411 | 0.161 |
| Fusion gene | χ=0.648 | 0.421 | ||
| Negative | 14 (60.87) | 39 (51.32%) | ||
| Positive | 9 (39.13%) | 37 (48.68%) | ||
| Risk stratification | χ=19.403 | 0.000 | ||
| Standard risk | 3 (13.04%) | 35 (46.05%) | ||
| Intermediate risk | 6 (26.09%) | 29 (38.16%) | ||
| High risk | 14 (60.87%) | 12 (15.79%) | ||
| MRD at 33 day | χ=3.709 | 0.054 | ||
| ≤10 | 11 (47.83%) | 53 (69.74%) | ||
| >10 | 12 (52.17%) | 23 (30.26%) | ||
| MRD at 12 week | χ=7.249 | 0.007 | ||
| ≤10 | 10 (43.48%) | 56 (73.68%) | ||
| >10 | 13 (56.52%) | 20 (26.32%) |